Company news
Lexicon Pharmaceuticals, Inc. news in 2020
Lexicon Pharmaceuticals, Inc.'s news releases, calls and decks from 2020, newest first.
Lexicon Pharmaceuticals Announces Commencement of Dosing in Phase 2 Clinical Study of LX9211 in Post-Herpetic Neuralgia
December 30, 2020
Lexicon Announces Offering of Common Stock
December 10, 2020
Lexicon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical Update
October 28, 2020
Lexicon Pharmaceuticals Reaches Agreements to Exchange Convertible Notes, Reduce Outstanding Indebtedness
September 22, 2020
Lexicon Pharmaceuticals Completes the Sale of XERMELO to TerSera Therapeutics
September 7, 2020
Lexicon Pharmaceuticals Announces Commencement of Patient Dosing in RELIEF-DPN-1 Phase 2 Clinical Study of LX9211 in Patients With Diabetic Peripheral Neuropathic Pain
September 3, 2020
Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program
July 29, 2020
Lexicon Pharmaceuticals Announces Topline Phase 3 Data From Four Phase 3 Sotagliflozin Studies in Type 2 Diabetes
July 20, 2020
Lexicon Pharmaceuticals Announces Poster Presentations at the Virtual Cholangiocarcinoma Foundation Annual Conference
July 19, 2020
Lexicon Pharmaceuticals Announces Preclinical Efficacy Data on Telotristat Ethyl’s Antiproliferative Effects Against Various Cancer Cell Lines
May 12, 2020
Lexicon Pharmaceuticals reports first quarter 2020 financial results and provides a business update
April 26, 2020
Lexicon Pharmaceuticals to host virtual annual meeting of stockholders on April 23, 2020
April 6, 2020
Lexicon Pharmaceuticals provides an update on the sotagliflozin type 2 diabetes program
March 18, 2020
Lexicon Pharmaceuticals announces additional data on telotristat ethyl’s antiproliferative effects in patients with carcinoid syndrome
March 12, 2020
Lexicon Pharmaceuticals reports fourth quarter and full-year 2019 financial results and provides a business update
March 11, 2020
Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome
January 23, 2020
Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium
January 19, 2020